General Information of Drug (ID: DM9MPHF)

Drug Name
4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine Drug Info
Synonyms CHEMBL1089985; 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine; SCHEMBL2239177; 1H-Pyrrolo[2,3-b]pyridine, 4-(1H-pyrazol-4-yl)-; BDBM50315770
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
46885627
TTD Drug ID
DM9MPHF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [2]
Indirubin-3'-monoxime DMLRQH0 Discovery agent N.A. Investigative [3]
SU 6656 DMF1P6W Discovery agent N.A. Investigative [4]
6-bromoindirubin-3-oxime DM12WYV Discovery agent N.A. Investigative [3]
7-fluoroindirubin-3-oxime DMQD34N Discovery agent N.A. Investigative [3]
PMID21742770C1 DME3JMH Discovery agent N.A. Investigative [5]
Indirubin-3-acetoxime DM3UR1E Discovery agent N.A. Investigative [3]
CGP-57380 DMFPOUC Discovery agent N.A. Investigative [4]
PMID20855207C25 DMNEB6J Discovery agent N.A. Investigative [6]
Indirubin-3-methoxime DMZ5ODC Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora kinase A (AURKA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT9283 DMQ94CT Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
MLN8237 DMO8PT9 Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [9]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [11]
ENMD-2076 DMJZVPB Acute myeloid leukaemia 2A60 Phase 2 [9]
LY3295668 DM8RJTB Solid tumour/cancer 2A00-2F9Z Phase 1/2 [12]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
MLN8054 DMUANF3 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
CYC116 DMUMHXT Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aurora B messenger RNA (AURKB mRNA) TT9RTBL AURKB_HUMAN Inhibitor [1]
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Inhibitor [1]

References

1 Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.
2 Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
3 An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
4 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
5 A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
6 Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
7 A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
8 Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
9 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
10 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
11 Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
12 Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
14 Clinical pipeline report, company report or official report of Cyclacel.